Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF)
A. Azuma, Y. Taguchi, T. Ogura, M. Ebina, H. Taniguchi, Y. Kondoh, M. Suga, H. Takahashi, K. Nakata, A. Sato, S. Kudoh, T. Nukiwa, Pirfenidone Clinical Study Group in Japan (Tokyo, Tenri City, Yokohama, Sendai, Aichi, Kumamoto, Japan)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Azuma, Y. Taguchi, T. Ogura, M. Ebina, H. Taniguchi, Y. Kondoh, M. Suga, H. Takahashi, K. Nakata, A. Sato, S. Kudoh, T. Nukiwa, Pirfenidone Clinical Study Group in Japan (Tokyo, Tenri City, Yokohama, Sendai, Aichi, Kumamoto, Japan). Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2010; 36: Suppl. 54, 387
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: